Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone

Reata Pharmaceuticals (Nasdaq:RETA) a clinical-stage biopharmaceutical company, today announced new preclinical data demonstrating that omaveloxolone potently activates the Keap1/Nrf2 pathway,...

TG Therapeutics Shows New Preliminary Data

TG Therapeutics revealed preliminary results from an ongoing Phase 2 study of TG-1101 treating patients with relapsing forms of multiple...